United Kingdom: These 3 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027

Generic name: deoxycholic acid
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2027
Generic Entry Controlled by: United Kingdom Patent 2,460,350

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and forty-six patent family members in thirty-eight countries. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. There are thirty-three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the deoxycholic acid profile page.

Generic name: beclomethasone dipropionate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 11, 2027
Generic Entry Controlled by: United Kingdom Patent 706,999

QVAR REDIHALER is a drug marketed by Norton Waterford. There are seventeen patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has two hundred and seventy-eight patent family members in twenty-seven countries. There has been litigation on patents covering QVAR REDIHALER

See drug price trends for QVAR REDIHALER.

The generic ingredient in QVAR REDIHALER is beclomethasone dipropionate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the beclomethasone dipropionate profile page.

Generic name: deoxycholic acid
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2027
Generic Entry Controlled by: United Kingdom Patent 807,615

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and forty-six patent family members in thirty-eight countries. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. There are thirty-three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the deoxycholic acid profile page.

Generic name: deoxycholic acid
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2027
Generic Entry Controlled by: United Kingdom Patent 912,493

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and forty-six patent family members in thirty-eight countries. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. There are thirty-three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the deoxycholic acid profile page.

Generic name: citric acid; magnesium oxide; sodium picosulfate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 12, 2027
Generic Entry Controlled by: United Kingdom Patent 805,953

PREPOPIK is a drug marketed by Ferring Pharms Inc. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has thirty-two patent family members in twenty-five countries. There has been litigation on patents covering PREPOPIK

See drug price trends for PREPOPIK.

The generic ingredient in PREPOPIK is citric acid; magnesium oxide; sodium picosulfate. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the citric acid; magnesium oxide; sodium picosulfate profile page.

Generic name: technetium tc-99m tetrofosmin kit
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: September 21, 2027
Generic Entry Controlled by: United Kingdom Patent 718,386

MYOVIEW 30ML is a drug marketed by Medi-physics. There is one patent protecting this drug.

This drug has eight patent family members in seven countries. There has been litigation on patents covering MYOVIEW 30ML

The generic ingredient in MYOVIEW 30ML is technetium tc-99m tetrofosmin kit. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the technetium tc-99m tetrofosmin kit profile page.